GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hospira Inc (FRA:HOS) » Definitions » Piotroski F-Score

Hospira (FRA:HOS) Piotroski F-Score : 7 (As of May. 05, 2024)


View and export this data going back to . Start your Free Trial

What is Hospira Piotroski F-Score?

Good Sign:

Piotroski F-Score of 7 is 7, indicating very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Hospira has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Hospira's Piotroski F-Score or its related term are showing as below:

FRA:HOS' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 6   Max: 8
Current: 7

During the past 13 years, the highest Piotroski F-Score of Hospira was 8. The lowest was 3. And the median was 6.


Hospira Piotroski F-Score Historical Data

The historical data trend for Hospira's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hospira Piotroski F-Score Chart

Hospira Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 5.00 5.00 3.00 7.00

Hospira Quarterly Data
Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 7.00 7.00 7.00 7.00

Competitive Comparison of Hospira's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Hospira's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hospira's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hospira's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Hospira's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun15) TTM:Last Year (Jun14) TTM:
Net Income was 123.074 + 29.034 + 69.854 + 129.284 = €351 Mil.
Cash Flow from Operations was 123.229 + 265.278 + -92.677 + 255.271 = €551 Mil.
Revenue was 892.866 + 913.591 + 1085.608 + 1054.588 = €3,947 Mil.
Gross Profit was 334.689 + 312.722 + 483.714 + 462.785 = €1,594 Mil.
Average Total Assets from the begining of this year (Jun14)
to the end of this year (Jun15) was
(4711.725 + 5038.646 + 5393.15 + 6051.83 + 6044.366) / 5 = €5447.9434 Mil.
Total Assets at the begining of this year (Jun14) was €4,712 Mil.
Long-Term Debt & Capital Lease Obligation was €1,558 Mil.
Total Current Assets was €2,682 Mil.
Total Current Liabilities was €1,063 Mil.
Net Income was 1.421 + 24.455 + 49.092 + 52.182 = €127 Mil.

Revenue was 754.134 + 791.612 + 759.728 + 835.949 = €3,141 Mil.
Gross Profit was 217.07 + 234.768 + 267.221 + 294.4 = €1,013 Mil.
Average Total Assets from the begining of last year (Jun13)
to the end of last year (Jun14) was
(4559.294 + 4512.086 + 4510.597 + 4452.017 + 4711.725) / 5 = €4549.1438 Mil.
Total Assets at the begining of last year (Jun13) was €4,559 Mil.
Long-Term Debt & Capital Lease Obligation was €1,287 Mil.
Total Current Assets was €2,253 Mil.
Total Current Liabilities was €877 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Hospira's current Net Income (TTM) was 351. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Hospira's current Cash Flow from Operations (TTM) was 551. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun14)
=351.246/4711.725
=0.07454722

ROA (Last Year)=Net Income/Total Assets (Jun13)
=127.15/4559.294
=0.02788809

Hospira's return on assets of this year was 0.07454722. Hospira's return on assets of last year was 0.02788809. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Hospira's current Net Income (TTM) was 351. Hospira's current Cash Flow from Operations (TTM) was 551. ==> 551 > 351 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun15)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun14 to Jun15
=1557.557/5447.9434
=0.28589816

Gearing (Last Year: Jun14)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun13 to Jun14
=1287.19/4549.1438
=0.28295215

Hospira's gearing of this year was 0.28589816. Hospira's gearing of last year was 0.28295215. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun15)=Total Current Assets/Total Current Liabilities
=2681.643/1062.696
=2.52343379

Current Ratio (Last Year: Jun14)=Total Current Assets/Total Current Liabilities
=2252.675/876.944
=2.56877862

Hospira's current ratio of this year was 2.52343379. Hospira's current ratio of last year was 2.56877862. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Hospira's number of shares in issue this year was 176.1. Hospira's number of shares in issue last year was 170. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1593.91/3946.653
=0.40386373

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1013.459/3141.423
=0.32261144

Hospira's gross margin of this year was 0.40386373. Hospira's gross margin of last year was 0.32261144. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun14)
=3946.653/4711.725
=0.8376238

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun13)
=3141.423/4559.294
=0.68901523

Hospira's asset turnover of this year was 0.8376238. Hospira's asset turnover of last year was 0.68901523. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+0+0+0+1+1
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Hospira has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Hospira  (FRA:HOS) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Hospira Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Hospira's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Hospira (FRA:HOS) Business Description

Traded in Other Exchanges
N/A
Address
Hospira Inc was incorporated in Delaware on September 16, 2003. The Company is a provider of injectable drugs and infusion technologies, and is also engaged in developing, manufacturing, marketing and distribution. Its portfolio includes generic acute-care and oncology injectables, biosimilars, and integrated infusion therapy and medication management products. Its portfolio of products is used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. The Company's business segments are Specialty Injectable Pharmaceuticals, Medication Management and Other Pharmaceuticals. Specialty Injectable Pharmaceuticals consists of generic injectable pharmaceuticals products. Generic injectable pharmaceuticals provide customers with a lower-cost alternative to branded products when associated patent protection expires, when patents are declared invalid, or when the generic products do not infringe the patents of others. Our generic injectable pharmaceuticals are sold in therapeutic areas including analgesia, anesthesia, anti-infectives, cardiovascular, oncology, and other. Medication Management offer the Hospira MedNet safety software system, which is designed for hospitals to customize intravenous drug dosage limits and track drug delivery to prevent medication errors. The wireless network version of the Hospira MedNet system establishes real-time send-and-receive capability and can interface with select hospital and pharmacy information systems. Other Pharmaceuticals primarily consists of large volume I.V. solutions, nutritionals and contract manufacturing services. We offer infusion therapy solutions and related supplies that include I.V. solutions for general use, I.V. nutrition products, and solutions for washing and cleansing of wounds or surgical sites. The Company's primary customers include hospitals, wholesalers, integrated delivery networks and alternate site facilities. Its competitors include Baxter International Inc.; Becton, Dickinson and Company; Fresenius Kabi AG; Mallinckrodt plc; Mylan Inc; Par Pharmaceuticals Companies, Inc.; Pfizer Inc.; Sandoz; Sanofi S.A. and Teva Pharmaceuticals, Aspen Medical; Fresenius Kabi; Pfizer; Sandoz and a number of smaller competitors and the originator companies. The Company's operations and business activities are subject to extensive legal and regulatory requirements that are enforced by numerous governmental agencies in the countries in which it do business.

Hospira (FRA:HOS) Headlines

No Headlines